Form 4: CONMED VP Controller Granted 5,896 RSUs

CONMED's VP Corporate Controller, Andrew James Moller, was granted 5,896 Restricted Stock Units under the company's 2025 Long-Term Incentive Plan.

Summary

• Andrew James Moller, CONMED Corp's VP Corporate Controller, received a grant of 5,896 Restricted Stock Units (RSUs).
• The RSUs were granted on March 2, 2026, with a transaction price of $0.
• Each RSU represents a contingent right to receive one share of CONMED Corporation common stock.
• The grant is subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan.
• The RSUs generally vest over a three-year period: 33% one year after the grant date, 33% in the second year, and 34% in the third year.
• Following this transaction, Andrew James Moller beneficially owns 5,896 derivative securities (RSUs).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it represents a routine executive compensation action that aligns management incentives with long-term shareholder value, without indicating any immediate operational or financial changes.

Positives

• The grant of 5,896 Restricted Stock Units (RSUs) to a key executive aligns management's interests with those of shareholders.
• Participation in the 2025 Long-Term Incentive Plan indicates a structured approach to executive compensation.

Negatives

• RSUs do not provide immediate cash value to the recipient.
• The vesting schedule means the shares are not fully owned until three years after the grant date, subject to continued employment.

Risks

• The value of the RSUs is subject to the future market price fluctuations of CONMED Corporation's common stock.
• RSUs are subject to forfeiture if the recipient's employment terminates before the vesting conditions are met.

Future Outlook

The grant of Restricted Stock Units implies a future issuance of 5,896 shares of common stock to Andrew James Moller, contingent upon the satisfaction of the three-year vesting schedule, which begins one year after the grant date.

Industry Context

StockSavvy.ai notes that the grant of Restricted Stock Units to a key executive like the VP Corporate Controller is a standard practice in the medical technology and broader corporate sectors. This form of equity compensation is widely used to attract, retain, and incentivize senior management by aligning their long-term financial interests with shareholder value creation.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential dilution upon vesting, but also increased alignment of executive interests with shareholder value creation.
• Employees: Standard executive compensation practices can positively influence morale and retention at senior levels.

Next Steps

• Vesting of 33% of the RSUs one year after the grant date (March 2, 2027).
• Vesting of an additional 33% of the RSUs two years after the grant date (March 2, 2028).
• Vesting of the final 34% of the RSUs three years after the grant date (March 2, 2029).

Key Dates

Keywords

CONMED, CNMD, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Form 4, Long-Term Incentive Plan, Corporate Governance